Karin Gembert

Artiklar

Article: BMJ OPEN. 2023;13(2):e066057
Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study
Reilev M; Jensen PB; Ranch LS; Egeberg A; Furu K; Gembert K; Hagg D; Haug U; Karlstad O; Reutfors J; Schaefer W; Schwartz S; Smits E; Holthius E; Herings R; Trifiro G; Kirchmayer U; Rosa AC; Belleudi V; Gini R; Stovring H; Hallas J
Article: NEUROLOGY AND THERAPY. 2022;11(4):1659-1676
Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study
Forns J; Dudukina E; Hagg D; Szentkuti P; Gembert K; Plana E; Gilsenan A; Horvath-Puho E; Ehrenstein V; Reutfors J; Rebordosa C
Article: CLINICAL EPIDEMIOLOGY. 2021;13:1141-1153
Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)
Arana A; Pottegard A; Kuiper JG; Booth H; Reutfors J; Calingaert B; Lund LC; Crellin E; Schmitt-Egenolf M; Kaye JA; Gembert K; Rothman KJ; Kieler H; Dedman D; Houben E; Gutierrez L; Hallas J; Perez-Gutthann S